An interventional study of Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery in Endometriosis, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.
Among the 128 studies in Endometriosis with a site in France, this one is the 61st largest by planned enrollment of the 70 interventional ones that give a count, is one of 15 that started in 2026, is one of 57 with no phase, reaches primary completion later than 42 of the 55 other live ones, and was the 106th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Limoges · Sites in France
Ages 18–50 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
Elsan · Sites in France
Ages 18–45 · Women only
ZIWIG · Sites in France
Ages 18–43 · Women only
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–40 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 6 · Phase 4 1
First in 1990; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 91 across the 70 interventional studies, 133 across the 58 observational. Of the 54 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 128 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 3 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
21 of the studies in Endometriosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973603Institut National de la Santé Et de la Recherche Médicale, FranceExposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort | 2026-12 |
| NCT04704115University Hospital, LilleThe Therapy of Large Endometrioma | 2026-12 |
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT07864883University Hospital, Strasbourg, France3D Modeling of Deep Endometriosis From Pelvic MRI | 2026-12-27 |
| NCT04554602Assistance Publique - Hôpitaux de ParisFusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 128 studies in Endometriosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. [18F]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of [18F]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.
Endometriosis is a chronic estrogen-dependent gynecological condition that leads to impaired overall quality of life due to infertility and associated pain. Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. There are several anatomo-clinical pathological entities. Thus, its painful symptoms vary greatly in its location and intensity. MRI, the reference examination for diagnosis but operator dependent, shows imperfect sensitivity. The diagnosis and characterization of lesions must therefore be improved. We know that 17β-estradiol, a key hormone for lesion growth, can also be produced locally by endometriotic tissue. The hypothesis according to which this local accumulation of estrogens plays an important role in the development of lesions by modulating the expression of RE must be studied. The use of new tools to study estrogen receptor expression should be evaluated at diagnosis. A new examination, [18F]-FES PET/CT, could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of the ER from the diagnosis and thus help to guide therapeutic care. [18F]-FES PET/CT is a non-invasive, operator-independent method that visualizes and quantifies ER expression in multiple tumors. Some studies have shown that [18F]-FES uptake correlates well with ER expression measured by immunohistochemistry staining. We will thus attempt to correlate the intensity of [18F]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases:
- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis;
Controls:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
Procedure: Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.
Quantification of Estrogen Receptor Overexpression in Endometriotic Lesions Using SUV on [18F]-FES PET/CT
Estrogen receptor (ER) overexpression in endometriotic lesions will be assessed using the Standardized Uptake Value (SUV) on preoperative \[18F\]-FES PET/CT imaging. Each lesion's SUV will be quantified and compared within patients and between groups with high pain levels (VAS ≥ 4) and low or no pain (VAS \< 4). ER overexpression is defined as increased \[18F\]-FES uptake compared to background levels. The correlation between SUV values and pain severity will be analyzed to determine whether ER overexpression is associated with symptomatic burden. Higher SUV values indicate greater ER expression.
Time frame: Preoperative assessment at mid-cycle, before surgery and without concurrent hormonal treatment.
Characterization of Lesion Staining by Immunohistochemistry and In Situ Hybridization: Intensity and Receptor Expression by Anatomical Location.
Lesions were analyzed using immunohistochemistry (IHC) and in situ hybridization to characterize receptor expression patterns (ERα, ERβ, GPER) and staining intensity. Tissue microarrays (TMA) from 20 patients were used to standardize analysis. IHC staining was performed with specific antibodies against ERα (SP1) and ERβ (CWK-F12 (DSHB)), while in situ hybridization was conducted using Bio-Techne probes targeting ESR1, ESR2, and GPER mRNA. Staining intensity and receptor expression were assessed for each lesion and compared across anatomical locations. Correlation with \[18F\]-FES PET/CT imaging and clinical symptomatology was also evaluated.
Time frame: From tissue collection at surgery to completion of immunohistochemical and in situ hybridization analyses (approximately 4 weeks post-surgery).
Sensitivity of [18F]-FES PET/CT Compared to MRI for Diagnosing Superficial and Deep Endometriotic Lesions by Anatomical Location.
The sensitivity of \[18F\]-FES PET/CT in detecting superficial and deep endometriotic lesions will be compared to that of MRI. Lesions will be classified based on their anatomical location. Sensitivity will be calculated as the proportion of true positive lesions detected by each imaging modality, using surgical and histopathological findings as the reference standard. The diagnostic performance of PET/CT and MRI will be analyzed for different lesion types and locations to assess their respective accuracy in detecting endometriosis.
Time frame: From completion of MRI and [18F]-FES PET/CT imaging (performed within 4 weeks prior to surgery) to histopathological analysis of lesions obtained during surgery (within 4 weeks post-imaging); total assessment period: up to 8 weeks per participant
Association Between [18F]-FES SUV Intensity, Estrogen Receptor Expression (IHC), and Pain Severity (VAS Score)
The association between \[18F\]-FES standardized uptake value (SUV) intensity, estrogen receptor (ER) expression assessed by immunohistochemistry (IHC), and pain severity will be analyzed. ER expression will be evaluated using specific antibodies for ERα and ERβ, and quantified based on staining intensity. Pain severity will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain). Correlations will be determined to assess the relationship between tracer uptake, receptor expression, and pain perception
Time frame: From the date of [18F]-FES PET/CT imaging (≤4 weeks before surgery) to the date of surgery and completion of pain assessments (VAS and BPI) and histopathological analysis of surgical samples; total duration of assessment per participant : up to 8 weeks
Correlation Between Estrogen Receptor Expression in IHC/ISH and Pain Intensity (VAS) in Endometriosis
Estrogen receptor expression (ERα, ERβ, GPER) will be assessed in endometriotic lesions using immunohistochemistry (IHC) and in situ hybridization (ISH). Staining intensity will be scored semi-quantitatively (e.g., 0 to 3). Pain severity will be measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain). A correlation analysis will be conducted to evaluate the relationship between receptor expression scores and VAS scores. The unit of measure will be the correlation coefficient between IHC/ISH scores and VAS units (0-10 scale).
Time frame: From surgery (biopsy collection) to completion of pain assessment and histological analysis; up to 8 weeks.
Correlation Between Estrogen Receptor mRNA Expression and Pain Intensity (VAS) in Endometriosis
Estrogen receptor mRNA expression (ESR1, ESR2, GPER) will be quantified in endometriotic lesions using in situ hybridization (ISH). Expression levels will be evaluated based on signal intensity scores derived from probe hybridization. Pain severity will be measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst pain). A statistical correlation will be assessed between the mRNA expression signal intensity scores and VAS values. The unit of measure will be the correlation coefficient quantifying the relationship between receptor expression levels and reported pain intensity.
Time frame: From surgery (biopsy collection) to completion of ISH and VAS assessments; up to 8 weeks.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 199 non-industry interventional studies with no phase under Endometriosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 24 months is close to that.
Counting every sponsor, half of 214 studies reached it within 25 months; a quarter within 13 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →